2024
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Pach J, Valido K, Belzer A, Leventhal J. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases. American Journal Of Clinical Dermatology 2024, 25: 595-607. PMID: 38767827, DOI: 10.1007/s40257-024-00866-z.Peer-Reviewed Original ResearchCutaneous immune-related adverse eventsImmune-related adverse eventsAdverse eventsAntitumor responseBiological agentsHigh-dose systemic corticosteroidsSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeCutaneous adverse reactionsAdverse event patternEnglish-language literatureTransient acantholytic dermatosisTreating high-gradeSpectrum of dermatologic manifestationsCheckpoint inhibitorsSystemic corticosteroidsCorticosteroid-sparingImmunobullous disordersPsoriasiform eruptionLichenoid reactionsEczematous dermatitisLichenoid eruptionDermatological manifestationsHigh-grade
2022
PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist
Belzer A, Bhullar S, Leventhal J. PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist. Current Dermatology Reports 2022, 11: 158-167. DOI: 10.1007/s13671-022-00365-6.Peer-Reviewed Original ResearchDermatologic adverse eventsBody surface areaClinical trialsAdverse eventsCommon dermatologic adverse eventsMucositis/stomatitisFrequent adverse eventsAddition of prednisoneMajority of malignanciesPI3K inhibitorsMaculopapular rashProphylactic therapyPsoriasiform eruptionTopical corticosteroidsSun avoidanceSummaryThis reviewPI3KiK inhibitorsInpatient DermatologistTrialsCancer therapyRashTherapyDermatologistsOverview of diagnostics